1st May 2019 07:00
Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to announce the appointment of Nplus1 Singer Advisory LLP (together with its associates, "N+1 Singer") as nominated adviser and UK corporate broker to the Company with immediate effect.
For further information contact:
| Verona Pharma plcJan-Anders Karlsson, Chief Executive OfficerVictoria Stewart, Director of Communications | Tel: +44 (0)20 3283 4200[email protected] |
| N+1 Singer (Nominated Adviser and UK Broker)Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance) Mia Gardner (Corporate Broking) | Tel: +44 (0)20 7496 3000 |
| ICR, Inc. (US Media and Investor enquiries)Darcie Robinson Stephanie Carrington | Tel: +1 203-919-7905[email protected]Tel. +1 646-277-1282[email protected] |
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, ensifentrine (RPL554), is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that has been shown to act as both a bronchodilator and an anti-inflammatory agent in a single compound. Ensifentrine is currently in Phase 2b clinical development for the maintenance treatment of COPD and is planned to enter Phase 3 trials for this indication in 2020. Verona Pharma is also developing ensifentrine for the treatment of cystic fibrosis and asthma.
Related Shares:
VRP.L